Sensorion, a clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has appointed Otmane Boussif as Chief Technical Officer.
Dr Boussif has more than 25 years experience in biologics, advanced therapy medicinal product, complex small molecules, vaccines, aseptic manufacturing operations and associated technical development, and partnering with contract development and manufacturing management. He joins Sensorion from Novartis, where he held a number of senior roles, including Global Head of Cell and Gene Therapy Technical Development and Global Head of Early Phase Development.
Before Novartis, Dr Boussif was Director of Purification and Formulation Processes for Vaccines at Sanofi Pasteur. He holds a Ph.D. in BioPhysico-Chemistry from the Université Louis Pasteur in Strasbourg and a Master in Organic Chemistry and BioChemistry also from ULP.
Dr Boussif brings with him considerable expertise in CMC development and implementation as well as a strong background in developing different biological modalities. In his new role, Dr Boussif will oversee all the technical operations and CMC functions at Sensorion.
Nawal Ouzren, CEO of Sensorion, said: “Dr Boussif is a cross functional leader who has been instrumental in shaping and leading successful global CMC organizations. He will play a vital role in the expansion of Sensorion's unique gene therapy platform, the small molecules CMC network strategy and his appointment highlights the acceleration of our product development programs.”